latest news releases from the newsroom
Much Shelist Freed Denenberg Ament & Rubenstein
Investors in Red Hat, Inc. have until September 13, 2004 to File Lead Plaintiff Petitions, says Chicago Law Firm Much Shelist -- RHAT
CHICAGO, Aug. 12, 2004 (PRIMEZONE) -- The deadline for purchasers of the securities of Red Hat ("Red Hat" or the "Company") (Nasdaq:RHAT) to move for lead plaintiff in a securities fraud class action brought by Much Shelist against Red Hat and certain of its officers and directors is rapidly approaching. If you purchased Red Hat securities between December 18, 2003 and July 12, 2004, inclusive ("Class Period") and you wish to be a lead plaintiff in the case, you must move to serve as lead plaintiff by filing a motion in the United States District Court for the Eastern District of North Carolina by September 13, 2004.
LifePoint, Inc. Releases Financial Results for the First Quarter Ended June 30, 2004
ONTARIO, Calif., Aug. 12, 2004 (PRIMEZONE) -- LifePoint, Inc. (AMEX:LFP), a leader in non-invasive drug diagnostic technologies and solutions, today announced financial results for the first quarter ended June 30, 2004. Net loss for the first quarter ended June 30, 2004 was $2.2 million, or $0.04 per share, compared to a net loss of $2.0 million, or $0.05 per share, for the first quarter ended June 30, 2003. Net loss applicable to common stockholders for the first quarter ended June 30, 2004 was $2.3 million, or $0.04 per share, compared to a net loss applicable to common stockholders of $2.4 million, or $0.06 per share for the first quarter ended June 30, 2003.
Discovery Laboratories, Inc.
Surfaxin Receives Orphan Drug Designation from European Commission
DOYLESTOWN, Pa., Aug. 12, 2004 (PRIMEZONE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that the Commission of the European Communities has designated Surfaxin(r) as an Orphan Medicinal Product. This designation is for the prevention of Respiratory Distress Syndrome (RDS) in premature neonates of less than 32 weeks of gestational age and for the treatment of RDS in premature neonates of less than 37 weeks of gestational age. Designation was granted following the positive opinion given by the Committee for Orphan Medicinal Products (COMP) of the European Medicines Evaluation Agency (EMEA) in which the COMP concluded that although satisfactory methods of prevention and treatment of RDS have been authorized in Europe, justifications have been provided that Surfaxin may be of significant benefit to those at risk of developing or affected by the condition.
Stratus Services Group, Inc.
Stratus Services Group, Inc. Announces Completion of Final Closing on Unit Offering
MANALAPAN, N.J., Aug. 12, 2004 (PRIMEZONE) -- Stratus Services Group, Inc., the SMARTSolutions(tm) Company (OTCBB:SSVG), announced today that it completed the final closing of its offering of up to a maximum of 12,500,000 units, with each unit consisting of one share of the Company's common stock and one common stock purchase warrant, after giving effect to its reverse split. The offering price was $.80 per unit. The exercise price of the warrants, each of which entitles the holder to purchase one share of common stock, is $.76 per share.